New York, New York--(Newsfile Corp. - February 4, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allarity Therapeutics, Inc. (NASDAQ: ALLR) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Allarity insiders caused the company to misrepresent or fail to disclose that (i) Dovitinib NDA's continued regulatory prospects were overstated; (ii) Allarity and three of its former officers had engaged in illegal, illicit, and/or otherwise improper conduct in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA; (iii) the foregoing misconduct subjected the Company to an increased risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; (iv) following Allarity's announcement that it was, in fact, being investigated for wrongdoing in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA, the Company downplayed the substantial likelihood that an enforcement action would result from such investigation; and (v) as a result, public statements were materially false and misleading at all relevant times.
If you currently own ALLR and purchased prior to May 17, 2022 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239578
